Garratty G, Arndt P A
Immunohematology Research Department, American Red Cross Blood Services, Southern California Region, Los Angeles 90006, USA.
Br J Haematol. 1998 Mar;100(4):777-83. doi: 10.1046/j.1365-2141.1998.00615.x.
A high incidence (39%) of positive direct antiglobulin tests (DATs) has been reported in patients taking Unasyn [ampicillin sodium plus sulbactam sodium (a beta-lactamase inhibitor)]. Three of four patients, with positive DATs, receiving Unasyn or Timentin [ticarcillin disodium plus clavulanate potassium (also a beta-lactamase inhibitor)] developed a haemolytic anaemia (HA) associated with a positive DAT, which resolved when drug therapy was stopped. The patients' sera did not react with red blood cells (RBCs) in the presence of Unasyn or Timentin, but when drug-treated RBCs were tested, patients' sera and normal sera reacted equally by indirect antiglobulin test. Following incubation in normal sera, RBCs treated with Unasyn, Timentin, Augmentin (amoxicillin + clavulanate), sulbactam and clavulanate reacted with anti-human globulin and anti-human albumin (an index of non-specific adsorption); RBCs treated with ampicillin and amoxicillin were nonreactive. The beta-lactamase inhibitors sulbactam and clavulanate seem to cause nonimmunologic adsorption of protein onto RBCs in vitro. This may explain the high incidence of positive DATs detected in patients taking Unasyn, which contains sulbactam. It was not possible to prove that there was a direct association between the nonspecific uptake of protein onto drug-treated RBCs in vitro with the positive DATs or the HA.
据报道,服用优立新(氨苄西林钠加舒巴坦钠,一种β-内酰胺酶抑制剂)的患者直接抗球蛋白试验(DAT)阳性发生率很高(39%)。在接受优立新或特美汀(替卡西林二钠加克拉维酸钾,也是一种β-内酰胺酶抑制剂)治疗且DAT阳性的4例患者中,有3例发生了与DAT阳性相关的溶血性贫血(HA),停药后贫血症状缓解。在有优立新或特美汀存在的情况下,患者血清不与红细胞(RBC)发生反应,但当检测经药物处理的RBC时,患者血清和正常血清通过间接抗球蛋白试验反应相同。在正常血清中孵育后,用优立新、特美汀、奥格门汀(阿莫西林+克拉维酸)、舒巴坦和克拉维酸处理的RBC与抗人球蛋白和抗人白蛋白发生反应(非特异性吸附指标);用氨苄西林和阿莫西林处理的RBC无反应。β-内酰胺酶抑制剂舒巴坦和克拉维酸似乎在体外可导致蛋白质非免疫性吸附到RBC上。这可能解释了服用含有舒巴坦的优立新的患者中检测到的DAT阳性发生率很高的原因。无法证明体外药物处理的RBC上蛋白质的非特异性摄取与DAT阳性或HA之间存在直接关联。